Medtronic (NYSE:MDT) Issues FY 2025 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its FY 2025 earnings guidance on Sunday morning. The company provided earnings per share guidance of 5.420-5.500 for the period, compared to the consensus earnings per share estimate of 5.440. The company issued revenue guidance of $33.5 billion-$33.8 billion, compared to the consensus revenue estimate of $33.4 billion.

Analyst Ratings Changes

A number of brokerages have weighed in on MDT. Daiwa America upgraded Medtronic to a strong-buy rating in a report on Friday, August 23rd. The Goldman Sachs Group began coverage on shares of Medtronic in a research report on Thursday, May 30th. They set a sell rating and a $83.00 target price on the stock. Royal Bank of Canada reaffirmed a sector perform rating and issued a $92.00 price target on shares of Medtronic in a research report on Wednesday, August 21st. Oppenheimer lifted their price objective on shares of Medtronic from $92.00 to $94.00 and gave the company a market perform rating in a report on Wednesday, August 21st. Finally, Stifel Nicolaus lifted their target price on Medtronic from $85.00 to $87.00 and gave the company a hold rating in a research note on Wednesday, August 21st. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and an average target price of $92.92.

Medtronic Trading Up 0.4 %

Shares of MDT opened at $88.58 on Monday. The stock has a market cap of $113.58 billion, a PE ratio of 32.21, a price-to-earnings-growth ratio of 2.52 and a beta of 0.82. Medtronic has a 52-week low of $68.84 and a 52-week high of $90.13. The firm’s fifty day moving average is $81.32 and its two-hundred day moving average is $82.42. The company has a quick ratio of 1.61, a current ratio of 2.13 and a debt-to-equity ratio of 0.55.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, August 20th. The medical technology company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.03. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. The business had revenue of $7.97 billion for the quarter, compared to analysts’ expectations of $7.90 billion. During the same period in the previous year, the firm posted $1.20 EPS. The business’s revenue for the quarter was up 3.4% compared to the same quarter last year. Research analysts forecast that Medtronic will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 11th. Stockholders of record on Friday, September 27th will be issued a $0.70 dividend. The ex-dividend date is Friday, September 27th. This represents a $2.80 annualized dividend and a dividend yield of 3.16%. Medtronic’s dividend payout ratio is currently 101.82%.

Insider Activity

In other news, CEO Geoffrey Martha sold 19,113 shares of the company’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $83.77, for a total transaction of $1,601,096.01. Following the sale, the chief executive officer now owns 143,348 shares of the company’s stock, valued at $12,008,261.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.30% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.